Approximately 10-20% of patients experience ongoing symptoms despite having received standard antibiotic therapy for Lyme disease. Possible explanations for persistent symptoms include persistent infection and/or post-infectious causes. Recent in vitro studies indicate that disulfiram is effective at killing both the actively replicating and the more quiescent persister forms of Borrelia burgdorferi, the microbe that causes Lyme Disease. In this study, the investigators are examining the safety of disulfiram among patients with post-treatment Lyme disease symptoms. The investigators are also conducting a preliminary investigation regarding the relative benefit of 4 vs 8 weeks of treatment with disulfiram.

Brief Title

Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease

Official Title

Disulfiram ("Antabuse"): A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease

Brief Summary

Approximately 10-20% of patients experience ongoing symptoms despite having received standard
antibiotic therapy for Lyme disease. Possible explanations for persistent symptoms include
persistent infection and/or post-infectious causes. Recent in vitro studies indicate that
disulfiram is effective at killing both the actively replicating and the more quiescent
persister forms of Borrelia burgdorferi, the microbe that causes Lyme Disease. In this study,
the investigators are examining the safety of disulfiram among patients with post-treatment
Lyme disease symptoms. The investigators are also conducting a preliminary investigation
regarding the relative benefit of 4 vs 8 weeks of treatment with disulfiram.

Detailed Description

Lyme disease, caused by the spirochete Borrelia burgdorferi, is the most common tick-borne
illness in the United States. Typically, after being bitten by an infected tick, patients
will notice an expanding rash and flu-like symptoms. Most patients recover fully after
initial treatment with antibiotics such as doxycycline or amoxicillin. Some patients,
however, do not recover fully or their symptoms return within a few months after having
completed antibiotic treatment. Common persistent symptoms include fatigue, joint pain,
muscle pain, numbness, tingling, burning pains, and changes in mood, memory or mental
clarity. These symptoms can last months to years after treatment and, when accompanied by
functional impairment, are collectively referred to by the academic community as "Post
Treatment Lyme Disease Syndrome (PTLDS)". Patients however typically refer to this
constellation of persistent symptoms as "Chronic Lyme Disease".

There are several possible explanations for why patients may have persistent symptoms,
including persistent infection and post-infectious changes triggered by the prior infection.

Scientists recently discovered that disulfiram is effective in the lab setting at killing the
microbes that cause Lyme disease. Disulfiram is more commonly known as "Antabuse". It is an
FDA-approved compound used to assist alcoholics in resisting alcohol consumption. Most
remarkable is that disulfiram was effective at killing not only the actively replicating Lyme
bacteria (ie, the ones that are typically killed by several antibiotics) but also the
relatively dormant or quiescent Lyme bacteria (these are called "drug-tolerant persisters") -
these latter spirochetes are the ones that may account for the development of chronic Lyme
disease symptoms.

This initial pilot study will focus on patients with persistent symptoms despite having
received the standard antibiotic therapy (or more) for Lyme disease. Because no one has yet
studied the safety of disulfiram for patients with a history of Lyme disease and because the
investigators do not know the optimal treatment duration for disulfiram, the initial effort
will have the primary aims of assessing safety and determining whether a longer course of
daily treatment is more effective than a shorter course of daily treatment.

The investigators propose therefore a small 14-week randomized placebo-controlled pilot study
enrolling 24 patients with persistent symptoms despite prior antibiotic treatment for Lyme
disease (known as Post-treatment Lyme Disease Syndrome). Among the 24 disulfiram-treated
patients, half will get 8 weeks of disulfiram and the other half will get a shorter duration
of disulfiram for 4 weeks followed by 4 weeks of matching placebo. After week 8, patients
will be off pills for 2 weeks for the primary week 10 evaluation and then for another 4 weeks
for the week 14 follow-up evaluation. This will be a double-blinded study; neither physician
nor patient will know which treatment group the patient is assigned to.

With this initial study, the investigators will be able to evaluate the side effects,
tolerability and initial signs of the effectiveness of disulfiram in reducing symptoms among
the 24 patients assessed. The results of this study will guide the investigators regarding
whether a larger definitive randomized trial should be conducted and which treatment schedule
is optimal.

Outcome Measures

Outcome measures are the tests that investigators perform to prove whether or not a treatment being tested in a clinical trial is having any effect.